Sergey Deyev

Sergey Deyev

Russian Academy of Sciences, Russia
Targeted Multifunctional Hybrid Agents for Oncotheranostics
Abstract:

An important task of successful cancer diagnostics and therapy is the introduction into the arsenal of modern oncology of a wide range of compounds with different mechanisms of action on cancer cells.
Focusing on these goals, a multifunctional agent was created for targeted delivery of two toxic agents — radionuclides and biological toxin — to cancer cells. Specifically, we synthesized hybrid complex, including upconversion nanoparticles (UCNP) doped with beta-emitting radionuclide yttrium-90, and a pseudomonas exotoxin A fragment equipped with the targeted scaffold polypeptide DARPin9.29 specific to tumor receptor HER2. It was shown that the synergistic effect of the simultaneous use of a radionuclide and a toxin is 2200 times stronger than when used separately.
We also developed dual targeting-based HER2-directed cancer cell therapy with biocompatible and biodegradable poly lactic-co-glycolic acid (PLGA) nanoparticles and targeted immunotoxin. The PLGA nanoparticles were equipped with: i) HER2 recognizing scaffold protein ZHER2:342, ii) fluorescent dye for cell imaging and iii) chemotherapeutic drug doxorubicin for cell killing. The capabilities of these multifunctional PLGA nanoparticles for cancer cell theranostics was demonstrated in vitro and in vivo. In order to enhance the targeted cytotoxic effect, we used targeted nanoparticles and a targeted bifunctional immunotoxin DARPin9.29-LoPE. LoPE is  low-immunogenic modification of Pseudomonas exotoxin A, which is promising for in vivo applications. We showed that such combined therapy with DARPin9.29-LoPE & PLGA*ZHER2:342 nanoparticles allows reducing the effective concentration of immunotoxin up to about 1000 times.
The results of our other studies on oncotheranostics will also be presented.